Contact
searchSearch
HMP Global

Renal Denervation Topic Center

Featured

Jeremy Bock, MD
Renal Denervation
Blood Pressure Response Following Radiofrequency Renal Denervation in a Large Commercial U.S. Cohort
03/21/2025
Jeremy S. Bock, MD, FACC, FSCAI
Dr. Jeremy Bock discusses his study looking at blood pressure response following radiofrequency renal denervation in the largest real-world United States cohort, including older patients, recently presented at the CRT meeting in Washington,...
Dr. Jeremy Bock discusses his study looking at blood pressure response following radiofrequency renal denervation in the largest real-world United States cohort, including older patients, recently presented at the CRT meeting in Washington,...
Dr. Jeremy Bock discusses his...
03/21/2025
Cath Lab Digest
Renal Denervation
Use of the Paradise™ Ultrasound Renal Denervation (uRDN) System for Treatment of Uncontrolled Hypertension
03/05/2025
Amir Kaki, MD, FACC, FSCAI
The Paradise ultrasound Renal Denervation (uRDN) System (Recor Medical, Inc.) uses circumferential ultrasound energy to thermally ablate and disrupt sympathetic nerves along the renal arteries.
The Paradise ultrasound Renal Denervation (uRDN) System (Recor Medical, Inc.) uses circumferential ultrasound energy to thermally ablate and disrupt sympathetic nerves along the renal arteries.
The Paradise ultrasound Renal...
03/05/2025
Cath Lab Digest
Dr Kandzari
ISET 2025
Will Renal Denervation Have an Important Role in the Treatment of Hypertension?
01/31/2025
David E. Kandzari, MD
David E. Kandzari, MD, FACC, MSCAI gave a presentation at ISET 2025 where he examined renal denervation as a potential new standard in hypertension treatment.
David E. Kandzari, MD, FACC, MSCAI gave a presentation at ISET 2025 where he examined renal denervation as a potential new standard in hypertension treatment.
David E. Kandzari, MD, FACC,...
01/31/2025
Vascular Disease Management
From Vascular Disease Management
Hypertension
Medtronic Announces CMS National Coverage Analysis for Symplicity™ Spyral Renal Denervation System
01/14/2025
The Symplicity Spyral RDN system, approved by the U.S. FDA in November 2023, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood...
The Symplicity Spyral RDN system, approved by the U.S. FDA in November 2023, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood...
The Symplicity Spyral RDN...
01/14/2025
Cath Lab Digest
Reimbursement
CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter
11/04/2024
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT...
CMS has granted transitional...
11/04/2024
Cath Lab Digest
Clinical Trials
TCT: SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
ESC 2024
Medtronic Statement on the 2024 European Society of Cardiology Guidelines for Hypertension and Renal Denervation
08/30/2024
Medtronic News Medtronic is encouraged by the new the European Society of Cardiology (ESC) 2024 guidelines, which upgraded renal denervation (RDN) as a class IIb recommendation, providing a safe and effective complementary care option for...
Medtronic News Medtronic is encouraged by the new the European Society of Cardiology (ESC) 2024 guidelines, which upgraded renal denervation (RDN) as a class IIb recommendation, providing a safe and effective complementary care option for...
Medtronic News Medtronic is...
08/30/2024
Cath Lab Digest
CMS
CMS Approves NTAP for Symplicity Spyral RDN System
08/13/2024
CMS posted its FY25 Inpatient Prospective Payment System (IPPS) Final Rule, which covers the New Technology Add-on Payment (NTAP) program.  In the final rule, CMS approved NTAP for the Symplicity Spyral™ catheter. The NTAP will go into effect...
CMS posted its FY25 Inpatient Prospective Payment System (IPPS) Final Rule, which covers the New Technology Add-on Payment (NTAP) program.  In the final rule, CMS approved NTAP for the Symplicity Spyral™ catheter. The NTAP will go into effect...
CMS posted its FY25 Inpatient...
08/13/2024
Cath Lab Digest
CMS
CMS Approves Additional Payment for Recor Medical’s Paradise Ultrasound Renal Denervation System in Hospital Inpatient Cases
08/13/2024
CMS approved a New Technology Add-On Payment (NTAP) for the Paradise™ Ultrasound Renal Denervation (uRDN) system when performed in the hospital inpatient setting. Availability of the NTAP will begin on October 1, 2024, using the ICD-10-PCS...
CMS approved a New Technology Add-On Payment (NTAP) for the Paradise™ Ultrasound Renal Denervation (uRDN) system when performed in the hospital inpatient setting. Availability of the NTAP will begin on October 1, 2024, using the ICD-10-PCS...
CMS approved a New Technology...
08/13/2024
Cath Lab Digest
Real-World Studies
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension With Ultrasound Renal Denervation
07/25/2024
The study will focus on gathering real-world safety and effectiveness data over five years from up to 1,000 patients, collaborating with research centers to help advance diversity and health equity within clinical trials. Building upon the...
The study will focus on gathering real-world safety and effectiveness data over five years from up to 1,000 patients, collaborating with research centers to help advance diversity and health equity within clinical trials. Building upon the...
The study will focus on...
07/25/2024
Cath Lab Digest
Cutting-Edge Procedures
Renal Denervation: How We Do It
05/01/2024

Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM

Director, Vascular Intervention, Beth Israel Deaconess Medical Center; Section Head, Interventional Cardiology and Vascular Research, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

 

Disclosures: Dr. Secemsky reports he is a consultant to Medtronic and his institution receives funding from Medtronic.

 

Eric A. Secemsky, MD, MSc, RPVI, FACC...
We have struggled for years with managing hypertension. In my own practice, I recognized that I only had so many tools to offer my patients, primarily medical therapy and suggestions on lifestyle changes. However, there were still patients...
We have struggled for years with managing hypertension. In my own practice, I recognized that I only had so many tools to offer my patients, primarily medical therapy and suggestions on lifestyle changes. However, there were still patients...
We have struggled for years with...
05/01/2024
Cath Lab Digest

Subscriber

Cath Lab Digest Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use